



FORM HDP-1449 (Based on Form PTO-1449)

PATENT AND TRADEMARK OFFICE
INFORMATION DISCLOSURE CITIGATION
(Use several sheets if necessary)

Sheet 1 of 3

ATTORNEY DOCKET NO.	SERIAL NO.
01414/1/US (Pfizer Ref. 27788A/USA)	10722,104
APPLICANT	
Daniel P. Becker, et al.	
FILING DATE	GROUP
11/25/2003	1614

U.S. PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Name	Class/ Subclass	Filing Date

FOREIGN PATENT DOCUMENTS

Ref. Desig.	Examiner's Initials	Document Number	Date	Country	Class/ Subclass	Translation Yes No
24.	SP	WO 99/09000	2/25/99	PCT	C07C 235/00	
25.		WO 99/25687	5/27/99	PCT	C07D 211/66	
26.		WO 99/29667	6/17/99	PCT	C07D 211/16	
27.		WO 00/46221	8/10/00	PCT	C07D 405/12	
28.		WO 00/50396	8/31/00	PCT	C07D 211/66	
29.		WO 00/59874	10/12/00	PCT	C07C 259/06	
30.		WO 00/69821	11/23/00	PCT	C07D 211/66	
31.		WO 02/092588	11/21/02	PCT	C07D 309/08	
32.		WO 03/091247	11/6/03	PCT	C07D 407/12	
33.		WO 2004/000811	12/31/03	PCT	C07D 213/34	
34.		EP 0 780 386	6/25/97	Europe	C07D 309/08	
35.		EP 0 994 104	4/19/00	Europe	C07C 317/44	
36.		EP 1 081 137	3/07/01	Europe	C07D 211/96	

Examiner: *Deborah Felling*

Date Considered: *02/17/06*

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

217349955

FORM HDP-1449 (Based on Form PTO-1449)		ATTORNEY DOCKET NO.	SERIAL NO.
PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary)		01414/1/US (Pfizer Ref. 27788A/USA)	10/722,104
Sheet 2 of 3		APPLICANT	
		Daniel P. Becker, et al.	
		FILING DATE	GROUP
		11/25/2003	1614

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Ref. Desig.	Examiner's Initials	
37.	DP	Brown, P.D., "Synthetic Inhibitors of Matrix Metalloproteinases," in <i>Matrix Metalloproteinases</i> , pp. 243-61 (Edited by Parks, W.C. & Mecham, R.P., Academic Press, San Diego, CA 1998).
38.		Denis et al., <i>Matrix metalloproteinase inhibitors: Present achievements and future prospects</i> , INVEST. NEW DRUGS, 15:175-185 (1997).
39.		Freije et al., <i>Molecular cloning and expression of collagenase-3, a novel human matrix metalloproteinase produced by breast carcinomas</i> , J BIOL. CHEM., 269(24):16766-16773 (1994).
40.		Gearing et al., <i>Processing of tumour necrosis factor-α precursor by metalloproteinases</i> , NATURE, 370:555-557 (1994).
41.		Gu et al., <i>S-Nitrosylation of Matrix Metalloproteinases: Signaling Pathway to Neuronal Cell Death</i> , SCIENCE, 297:1186-90 (2002).
42.		Kenyon et al., <i>A model of angiogenesis in the mouse cornea</i> , INVEST. OPHTHALMOL. VIS. SCI., 37(8):1625-1632 (1996).
43.		Knight et al., <i>A novel coumarin-labelled peptide for sensitive continuous assays of the matrix metalloproteinases</i> , FEBS LETT., 296(3):263-266 (1992).
44.		Kuzmic et al., <i>High-throughput enzyme kinetics: Simultaneous determination of tight-binding inhibition constants and enzyme concentration</i> , ANAL. BIOCHEM., 286(1):45-50 (2000).
45.		Luckow et al., <i>Efficient generation of infectious recombinant baculoviruses by site-specific transposon-mediated insertion of foreign genes into a baculovirus genome propagated in escherichia coli</i> , J. VIROL., 67:4566-4579 (1993).
46.		McGeehan et al., <i>Regulation of tumour necrosis factor-α processing by a metalloproteinase inhibitor</i> , NATURE, 370:558-561 (1994).
47.		Mitchell et al., <i>Cloning, expression, and type II collagenolytic activity of matrix metalloproteinase-13 from human osteoarthritic cartilage</i> , J. CLIN. INVEST. 97(3):761-768 (1996).
48.		Rasmussen et al., <i>Matrix metalloproteinase inhibition as a novel anticancer strategy: a review with special focus on batimastat and marimastat</i> , PHARMACOL. THER., 75(1):69-75 (1997).
49.		Reboul et al., <i>The new collagenase, collagenase-3, is expressed and synthesized by human chondrocytes but not by synoviocytes</i> , J. CLIN. INVEST., 97(9):2011-2019 (1996).
50.		Schwartz et al., <i>Synthetic inhibitors of bacterial and mammalian interstitial collagenases</i> , PROG. IN MED. CHEM., 29:271-334 (1992).
51.		Tang, B. L., <i>ADAMTS: A Novel Family of Extracellular Matrix Proteases</i> , INT. J. BIOCHEM. CELL BIO., 33(11):33-44 (2001).

Examiner: Sarah Faling Date Considered: 02/17/06

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

FORM HDP-1449 (Based on Form PTO-1449) PATENT AND TRADEMARK OFFICE INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) Sheet 3 of 3	ATTORNEY DOCKET NO.	SERIAL NO.
	01414/1/US (Pfizer Ref. 27788A/USA)	10/722,104
	APPLICANT	
	Daniel P. Becker, et al.	
	FILING DATE	GROUP
11/25/2003	1614	

OTHER DOCUMENTS (including Author, Title, Date, Pertinent Pages, etc.)		
Ref. Desig.	Examiner's Initials	
52.	SP	Woessner, J.F., "The Matrix Metalloprotease Family" in <i>Matrix Metalloproteinases</i> , pp.1-14 (Edited by Parks, W.C. & Mecham, R.P., Academic Press, San Diego, CA 1998).
'53.	SP	Search Report and Preliminary Examination Report for International Application No. PCT/US03/37942

Examiner: <u>Sarah Pulsifer</u>	Date Considered: <u>02/17/06</u>
---------------------------------	----------------------------------

EXAMINER: Please initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.